Business Wire

Eaton Unveils Next-generation Architecture to Advance 800 VDC Power Infrastructure for AI Factories

13.10.2025 18:00:00 EEST | Business Wire | Press release

Share

Intelligent power management company Eaton today announced the delivery of a new reference architecture designed to accelerate the adoption of 800 VDC power in artificial intelligence (AI) data centers. Eaton’s new design, built in support of the 800 VDC architecture announced by NVIDIA, leverages Eaton’s innovative power management technology to protect and optimize high-density computing infrastructure and serves as a critical milestone in Eaton’s grid-to-chip strategy for meeting the increasing energy demands of AI data centers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251010367772/en/

Eaton’s new reference architecture is a key milestone in its collaboration with NVIDIA to accelerate 800 VDC power infrastructure in AI factories.

Data center energy load growth, driven by increasingly demanding AI workloads, continues to expand beyond the limits of existing data center capabilities. NVIDIA is working with leading power, silicon and data center partners to pioneer the adoption of 800 VDC and help unlock new levels of scalability and energy optimization in AI factories. These next-generation systems, which feature power distribution integrated with energy storage, are uniquely positioned to handle the power demands of modern AI factories, delivering megawatt-scale rack power safely, efficiently and with minimal material and infrastructure costs.

Eaton’s reference design incorporates Eaton solutions with NVIDIA AI infrastructure. Eaton products featured in the design include supercapacitors for fast-cycle power backup; power distribution technology through busbar included in the ORV3 design; a hot aisle containment system to support busway and cable trays within the application; DC connectors and more.

“The introduction of 800 VDC architectures is a transformative advancement for data center innovation that will enable new possibilities in AI computing,” said JP Buzzell, vice president and data center chief architect at Eaton. “We’re proud to deepen our collaboration with NVIDIA with the introduction of this new reference design, a major step in our grid-to-chip strategy, as we help accelerate the transition to the AI factory of the future.”

Eaton’s grid-to-chip strategy is a comprehensive approach to providing intelligent solutions for the full AI data center power chain, including power distribution, backup power and digital technologies. Other recent advancements in Eaton’s strategy include its collaboration with Siemens Energy to support fast construction of modular data centers with integrated on-site power generation as well as its new edge-based solution to detect and proactively mitigate AI power bursting in data centers.

“Streamlined 800 VDC architectures enable AI infrastructure to meet rising workload demands while maximizing energy efficiency,” said Dion Harris, senior director, HPC, Cloud and AI Infrastructure at NVIDIA. “NVIDIA’s collaboration with innovators like Eaton is paving the way for high-density computing environments built for the AI industrial age.”

Eaton will showcase its latest developments for the 800 VDC architecture in booth A15 at the Open Compute Project Global Summit, taking place October 13-16, 2025, in San Jose, California. To learn more about Eaton’s grid-to-chip power management solutions for AI data centers, visit Eaton.com/DataCenters.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re helping to solve the world’s most urgent power management challenges and building a more sustainable society for people today and generations to come.

Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251010367772/en/

Contacts

Eaton
Kristin Somers
+1.919.345.3714
Kristincsomers@eaton.com

Mark Van Hook
Largemouth Communications
+1.978.495.1851
mark@largemouthpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye